Leprosy Therapy, Past and Present: Can We Hope to Eliminate It?

Overview

Journal Indian J Dermatol

Specialty Dermatology

Date 2011 Mar 25

PMID 21430881

Citations 13

Authors

P V S Prasad

P K Kaviarasan

Affiliations

Soon will be listed here.

Abstract

Leprosy remains an important problem globally. Timely detection of new cases and prompt treatment with MDT continue to be the main intervention strategies. We review the various issues related to classification, treatment, drug resistance and the possible steps to eliminate the disease in the near future. The need for newer anti leprosy agents has been felt and various agents like fluroquinolones, macrolides and minocycline have all been tried in various combinations and duration. Uniform MDT in all leprosy patients might be a logical one too. Drug resistance can be identified by PCR based DNA sequence analysis which saves much time. Drugs like thalidomide analogues, pentoxifylline, selective cytokine inhibitory drugs have proved effective in controlling type-2 reaction in leprosy patients. New drugs for leprosy reactions are still needed. Far from being eliminated as a public health problem, leprosy still causes a considerable long term morbidity in both developing and developed world. New treatment and the optimal length of MDT requires further research. We need genome based technology to address the unresolved issues of transmission of M. leprae.

Citing Articles

Derivation of a Precise and Consistent Timeline for Antibiotic Development.

Stennett H, Back C, Race P Antibiotics (Basel). 2022; 11(9).

PMID: 36140015 PMC: 9495031. DOI: 10.3390/antibiotics11091237.

Concurrent pulmonary tuberculosis and lepromatous leprosy in a newly diagnosed HIV positive patient: a case report.

Masuka J, Mkhize Z, Pillay S, Mosam A BMC Pulm Med. 2021; 21(1):207.

PMID: 34193098 PMC: 8247149. DOI: 10.1186/s12890-021-01572-w.

Drug Delivery Systems on Leprosy Therapy: Moving Towards Eradication?.

Chaves L, Patriota Y, Soares-Sobrinho J, Vieira A, Costa Lima S, Reis S Pharmaceutics. 2020; 12(12).

PMID: 33322356 PMC: 7763250. DOI: 10.3390/pharmaceutics12121202.

Spectrum of leprosy among suspected cases attending a teaching hospital in Western Rajasthan, India.

Kalita J, Nag V, Yedale K J Family Med Prim Care. 2020; 9(6):2781-2784.

PMID: 32984125 PMC: 7491769. DOI: 10.4103/jfmpc.jfmpc_77_20.

Leprosy piRnome: exploring new possibilities for an old disease.

Pinto P, da Silva M, Moreira F, Bouth R, Gobbo A, Sandoval T Sci Rep. 2020; 10(1):12648.

PMID: 32724108 PMC: 7387468. DOI: 10.1038/s41598-020-69355-7.

References

Ji B, Sow S, Perani E, Lienhardt C, Diderot V, Grosset J . Bactericidal activity of a single-dose combination of ofloxacin plus minocycline, with or without rifampin, against Mycobacterium leprae in mice and in lepromatous patients. Antimicrob Agents Chemother. 1998; 42(5):1115-20. PMC: 105755. DOI: 10.1128/AAC.42.5.1115. View

Mathur N, Mittal A, Mathur D, Jain S . Long-term follow up of lepromatous leprosy patients receiving intralesional recombinant gamma-interferon. Int J Lepr Other Mycobact Dis. 1992; 60(1):98-100. View

Declercq E . "Guide to eliminate leprosy as a public health problem" (first edition, 2000, World Health Organization). Int J Lepr Other Mycobact Dis. 2001; 69(1):34-5. View

Deps P, Alves B, Gripp C, Aragao R, Guedes B, Filho J . Contact with armadillos increases the risk of leprosy in Brazil: a case control study. Indian J Dermatol Venereol Leprol. 2008; 74(4):338-42. DOI: 10.4103/0378-6323.42897. View

Ji B, Truffot-Pernot C, Lacroix C, Raviglione M, OBrien R, Olliaro P . Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice. Am Rev Respir Dis. 1993; 148(6 Pt 1):1541-6. DOI: 10.1164/ajrccm/148.6_Pt_1.1541. View

Meima A, Gupte M, Van Oortmarssen G, Habbema J . Trends in leprosy case detection rates. Int J Lepr Other Mycobact Dis. 1997; 65(3):305-19. View

Katoch K, Katoch V, Natrajan M, Sharma V, Singh H, Gupta U . Chemotherapy trials in MB leprosy using conventional and newer drugs pefloxacin and minocycline. Indian J Dermatol Venereol Leprol. 2010; 66(1):18-25. View

Scollard D, Adams L, Gillis T, Krahenbuhl J, Truman R, Williams D . The continuing challenges of leprosy. Clin Microbiol Rev. 2006; 19(2):338-81. PMC: 1471987. DOI: 10.1128/CMR.19.2.338-381.2006. View

. Chemotherapy of leprosy for control programmes. World Health Organ Tech Rep Ser. 1982; 675:1-33. View

10.

Rao P, Lakshmi T . 'Final push of leprosy' in India: What is being pushed?. Indian J Dermatol Venereol Leprol. 2006; 71(4):226-9. DOI: 10.4103/0378-6323.16611. View

11.

Gillis T . Is there a role for a vaccine in leprosy control?. Lepr Rev. 2008; 78(4):338-42. View

12.

Ellard G, Pannikar V, Jesudasan K, Christian M . Clofazimine and dapsone compliance in leprosy. Lepr Rev. 1988; 59(3):205-13. DOI: 10.5935/0305-7518.19880026. View

13.

Maeda S, Matsuoka M, Nakata N, Kai M, Maeda Y, Hashimoto K . Multidrug resistant Mycobacterium leprae from patients with leprosy. Antimicrob Agents Chemother. 2001; 45(12):3635-9. PMC: 90887. DOI: 10.1128/AAC.45.12.3635-3639.2001. View

14.

Jacobson R . Needed research in chemotherapy of leprosy related to the individual patient. Int J Lepr Other Mycobact Dis. 1996; 64(4 Suppl):S16-20. View

15.

Scollard D . Leprosy research declines, but most of the basic questions remain unanswered. Int J Lepr Other Mycobact Dis. 2005; 73(1):25-7. DOI: 10.1489/1544-581X(2005)73[25:LRDBMO]2.0.CO;2. View

16.

Fine P, Warndorff D . Leprosy by the year 2000--what is being eliminated?. Lepr Rev. 1997; 68(3):201-2. DOI: 10.5935/0305-7518.19970027. View

17.

. WHO Expert Committee on Leprosy. World Health Organ Tech Rep Ser. 1998; 874:1-43. View

18.

Girdhar B, Girdhar A, Chakma J . Advances in the treatment of reactions in leprosy. Indian J Lepr. 2007; 79(2-3):121-34. View

19.

Matsuoka M, Kashiwabara Y, Namisato M . A Mycobacterium leprae isolate resistant to dapsone, rifampin, ofloxacin and sparfloxacin. Int J Lepr Other Mycobact Dis. 2001; 68(4):452-5. View

20.

Daumerie D . Current World Health Organization-sponsored studies in the chemotherapy of leprosy. Lepr Rev. 2001; 71 Suppl:S88-90. DOI: 10.5935/0305-7518.20000075. View